Compare KYN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | AUPH |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2014 |
| Metric | KYN | AUPH |
|---|---|---|
| Price | $13.61 | $15.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 417.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 0.71 | 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ $19.48 | $61.48 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $11.31 | $7.29 |
| 52 Week High | $14.70 | $16.88 |
| Indicator | KYN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 43.85 |
| Support Level | $12.93 | $14.53 |
| Resistance Level | $14.37 | $15.23 |
| Average True Range (ATR) | 0.25 | 0.53 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 3.16 | 7.20 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.